News

Martha Gulati, MD, joins episode 2 to discuss the burden of gender disparity in cardiovascular research, screening and care.

A discussion with Dr. Lal on the successful trials and recent approval of dupilumab as a treatment for skin inflammation.

Data indicates a greater number of physicians is a better predictor of melanoma diagnoses than UV radiation rates.

The SpyGlass IOL platform showcased a 45% drop in mean intraocular pressure at 3 months in first-in-human glaucoma trial.

"Especially when untreated and in late stages of progression, ILD is well known to impact health related quality of life," according to Dr. Briana DiSilvio. "Chronic dyspnea, cough, and reduced exercise capacity can become disabling."

Safety data of the bioerodible sustained delivery intravitreal anti-VEGF treatment indicate no ocular or systemic serious adverse events with mild adverse events.

An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.

A discussion into safety data from the Phase 3 DERBY and OAKS trials on pegcetacoplan with Dr. Boyer at AAO 2022.

The risk of cirrhosis increased supramultiplicatively in patients with obesity, with excessive drinking, and who were homozygous carriers.

ADHD and ODD dimensions were associated differently with different types of impulsivity, with unique patterns of network connectivity.

Breaking phase 3 data were just announced from the results of the daridorexant (Quviviq) clinical trial for adults with insomnia in Japan.

A profound escalation in the frequency of nightmares, independently associated with suicide risk, occurred alongside related sleep and mental health outcomes during the COVID-19 pandemic.

New data from AAO 2022 show how technology may refine a currently inefficient enrollment practice for retina disease assessment.

Two-year results from YOSEMITE and RHINE suggest that the positive results of faricimab for DME in year one carried into second year. Dr. Caroline Baumal joins for an in-depth discussion on the findings.

A real-world comparison of the anti-VEGF agents suggests certain doses are associated with more likelihood of retreatment.

Faricimab treatment for both DME and nAMD was able to reliably get to 16 week dosing in 60% of eyes from YOSEMITE and RHINE and TENAYA and LUCERNE.

A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.

Findings from the INSIGHT study suggest MYL-1701P may provide a new anti-VEGF biosimilar option to patients with the common form of vision loss.

The 48-week results suggest robust CST reduction and visual gains with faricimab up to every 16 week dosing, comparable with aflibercept ever 8-weeks.

Dr. Yeh discusses how Innovations in AI may improve access for patients in resource limited setting and improve detection of vision-threatening diseases.

The data show 80% of patients were rescue-free up to 6 months with a single OTX-TKI implant injection.

A significant rate of reduction of geographic atrophy growth with pegcetacoplan was observed in both DERBY and OAKS over a 24-month period.

A look into major takeaways on efficacy, safety and functional data from the DERBY and OAKS trials on pegcetacoplan.

In this special edition episode of Don’t Miss a Beat, which was filmed on-site at the HFSA 2022 annual scientific meeting, hosts Muthiah Vaduganathan, MD, MPH, codirector of Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Stephen Greene, MD, assistant professor of medicine at Duke University School of Medicine, take the audience on a deep dive into implementation science at the meeting, the potential for a polypill in heart failure, and other highlights from HFSA 2022.

Brolucizumab was deemed superior to aflibercept in treatment naive patients with neovascular age-related macular degeneration.

New AAO 2022 data show the novel treatment administration may eventually save patients money versus standard anti-VEGF injfections.

New findings show the investigative single-dose agent is safe and associated with reduced rescue-dose anti-VEGF treatment.

Comparison of 12- and 24-month regimens of common nAMD treatment show little difference in the common adverse event in patient eyes.